Diagnosis and treatment of diseases and conditions of the intestinal tract

A method for determining an increased risk of CRC in a subject, comprising the steps of:

• (a) measuring the nucleic acid level of one or more of SEQ ID NOs:
• 1-318 in a sample collected from the subject using amplification and one or more pairs of primers specific for each of the one or more of SEQ ID NOs:
• 1-318;
• and
• (b) using the amplification results to determine whether the level of one or more of SEQ ID NOs:
• 1-318 is changed relative to a respective reference level for SEQ ID NOs:
• 1-318, thereby determining an increased risk of CRC for the subject.

A kit for diagnosing colorectal cancer (CRC) in a subject, the kit comprising:

• (a) polypeptides or polynucleotides capable of determining the level of one or more of SEQ ID NOs:
• 1-318 in a sample from the subject;
• and
• (b) instructions for use of the polypeptides or polynucleotides to determine the level of one or more of SEQ ID NOs:
• 1-318 in the sample from the subject, wherein a change in the level of one or more of SEQ ID NOs:
• 1-318 relative to a respective reference level for SEQ ID NOs:
• 1-318 indicates that the subject is likely to have a CRC.

A method of treating a subject having a CRC, the method comprising the steps of:

• (a) measuring the nucleic acid level of one or more of SEQ ID NOs:
• 1-318 in a sample collected from the subject, wherein a level of one or more of SEQ ID NOs:
• 1-318 that is changed relative to a respective reference level for SEQ ID NOs:
• 1-318 indicates that the subject is likely to have a CRC;
• and
• (b) treating a subject who has been determined to have an increased risk of CRC with a method selected from the group consisting of surgery, chemotherapy, an immunotherapy targeting VEGF, an immunotherapy targeting EGFR, an anti-BRAF therapy, a kinase inhibitor, a checkpoint inhibitor, and FMT.

A method of treating a subject having a CRC, the method comprising the steps of:

• (a) measuring the nucleic acid level of each of SEQ ID NOs:
• 1-318 in a sample collected from the subject, wherein a level of at least 50% of SEQ ID NOs:
• 1-318 that is changed relative to a respective reference level for SEQ ID NOs:
• 1-318 indicates that the subject is likely to have a CRC, thereby determining an increased risk of CRC for the subject;
• and
• (b) treating a subject who has been determined to have an increased risk of CRC with a method selected from the group consisting of surgery, chemotherapy, an immunotherapy targeting VEGF, an immunotherapy targeting EGFR, an anti-BRAF therapy, a kinase inhibitor, a checkpoint inhibitor, and FMT.